⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938676 | 0.71 | — | — | |
| SCHEMBL2748112 | 0.66 | — | — | |
| SCHEMBL1995763 | 0.58 | — | — | |
| SCHEMBL2044214 | 0.55 | — | — | |
| SCHEMBL3708515 | 0.53 | — | — | |
| SCHEMBL3339 | 0.50 | — | — | |
| SCHEMBL972586 | 0.50 | — | — | |
| SCHEMBL10840029 | 0.48 | — | — | |
| SCHEMBL350437 | 0.47 | — | — | |
| SCHEMBL1629367 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897918-B2 | Compositions and methods to increase production | Seqirus UK Limited (GB) | 2024-02-13 | — | — | US | disclosed |
| CN-106471119-B | Compositions and methods for increasing yield | 思齐乐 | 2020-11-10 | — | — | CN | disclosed |
| EP-3131578-B1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | SEQIRUS UK LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-20200040040-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | NOVARTIS (CH) | 2020-02-06 | — | — | US | disclosed |
| EP-3131578-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Novartis AG (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044216-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Seqirus UK Limited (GB) | 2017-02-16 | — | — | US | disclosed |
| WO-2015158605-A1 | HETARYL SUBSTITUTED MALONONITRILE COMPOUNDS | BASF SE (DE) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015158927-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | NOVARTIS AG (CH) | 2015-10-22 | — | — | WO | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| US-6265408-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT | SMITHKLINE BEECHAM PLC (GB) | 2001-07-24 | — | — | US | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0912512-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048681-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0269859-B2 | Pyrazolotriazine compounds | OTSUKA PHARMA CO LTD (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0399267-A2 | 8-Substituted-4-(heterocyclylmethylamino)-quinolines, their use and drugs prepared from them | BASF Aktiengesellschaft (DE) | 1990-11-28 | — | — | EP | disclosed |
| US-4824834-A | TREATING GOUT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0269859-A2 | Pyrazolotriazine compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |